Mallinckrodt PLCOTC Pink - Current Information:MCKPF
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range---
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 5, 2024
Press Release: Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance, from 6:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
6:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Endo Inc | 1.9B | 0.4x | --- |
Emergent BioSolutions Inc | 509.3M | -2.3x | --- |
Amneal Pharmaceuticals Inc | 2.6B | -12.2x | --- |
Tilray Brands Inc | 1.2B | -4.8x | --- |
Pacira Biosciences Inc | 802.5M | -8.1x | --- |
Company Information
Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
Contact Information
- Headquarters
- College Business & Technology Park Cruiserath, Blanchardstown, Dublin 15DUBLIN, Ireland
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Paul Bisaro
- President, Chief Executive Officer, Director
- Sigurdur Olafsson
- Chief Financial Officer, Executive Vice President
- Bryan Reasons
- Executive Vice President, Chief Compliance Officer
- Kassie Harrold
- Executive Vice President, Chief Legal Officer, Corporate Secretary
- Mark Tyndall
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6M |
|---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 19.7M |
Mallinckrodt PLC does not pay a dividend. | |
Beta | --- |
EPS | $20.19 |
Book Value | $58.90 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | 0.0x |
Operating Margin | 19.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
